Share of Broadcom (AVGO) just split 10:1, bringing its stock price down to $169. While the split won’t impact the stock fundamentally, it is far more attractive to more investors at this lower price. As noted by Seeking Alpha, analysts at TD Cowen “added that there...
by Ian Cooper Bitcoin may have bottomed out. Fears of further downside in the digital currency appear to be fading, with Germany running out of BTC to sell. “Data from Arkham shows that the wallet used by the German government to transfer BTC is now out of funds,” as...
It looks like Bitcoin has bottomed out. All as fears of further downside appear to be fading, with Germany running out of BTC to sell. “Data from Arkham shows that the wallet used by the German government to transfer BTC is now out of funds,” as noted by...
Weakness in an opportunity in Nike (NKE). The company just cut its revenue forecast, now expecting FY25 sales to be down mid-single-digits with sales in the first half of the year down by high-single-digits. For Q1, the company is expecting revenue to drop 10% with...
More than $1 trillion could be spent on artificial intelligence. In fact, according to Goldman Sachs, “The investment banking firm estimates that around $1 trillion will be spent over the next few years on data centers, semiconductors, grid upgrades, and other AI...
That was fast. On July 10, we said, “Oversold shares of First Solar are starting to pivot higher. After slipping from about $310 to $214.37 following the presidential debate, it appears to have found strong support." At the time, FSLR traded at about $227. By...
Gold prices could rally to $3,000 by year-end, says Goldman Sachs. The firm “sees continued tailwinds for gold amid an ongoing flight to safety due to geopolitical risks, continued buying of the commodity by central banks, and rising demand among Asian...
Oversold shares of First Solar (FSLR) are starting to pivot higher. After slipping from about $310 to $214.37 following the presidential debate, it appears to have found strong support. It’s also starting to pivot from over-extensions on RSI, MACD and Williams’ %R....
by Ian Cooper Biotech has been one of the most explosive sectors of the year. And it’ll get even better. Combined with new innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, a resurgence of M&A, and weight loss drug...
Keep an eye on rebounding shares of Salesforce.com (CRM). After plummeting from about $270 to about $212 on poor earnings and guidance, CRM is now back to $263.19. From here, we’re looking for an initial bearish gap refill around $270. After that, we’re also looking...